Healthcare provider profile · identity verified

Sarang Patel

Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ROYAL OAK, MI · NPI 1841660412

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sarang Patel received $161,530.52 in general payments during 2025 across 321 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 54.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 14 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Ingrezza, Lybalvi, Qelbree, Rexulti, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lybalvi by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Auvelity by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Caplyta by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.

Supernus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Qelbree as an associated drug or biological on 61278 records involving 18421 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qelbree by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$161,530.52

321 reported records · 12 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$87,459.10	54.1%	128	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$21,851.96	13.5%	40	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$18,900.21	11.7%	49	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$12,175.13	7.5%	40	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$8,105.08	5.0%	18	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$6,141.38	3.8%	27	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$5,834.72	3.6%	12	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$979.00	0.6%	2	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$30.19	0.0%	2	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$19.85	0.0%	1	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$17.36	0.0%	1	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$16.54	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$122,694.00	73
Honoraria	$18,750.00	17
Travel and Lodging	$10,472.73	45
Food and Beverage	$6,013.79	183
Consulting Fee	$3,600.00	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$87,459.10	128	2025
Source payment records 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.07 · Open Payments source 2025-01-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.88 · Open Payments source 2025-01-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,100.00 · Open Payments source 2025-01-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $103.00 · Open Payments source 2025-02-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.35 · Open Payments source 2025-02-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,925.00 · Open Payments source 2025-02-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $210.00 · Open Payments source 2025-02-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.85 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.70 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,375.00 · Open Payments source 2025-02-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.86 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $220.50 · Open Payments source 2025-03-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.47 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $104.75 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,375.00 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $133.00 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.08 · Open Payments source 2025-05-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.46 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.94 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.59 · Open Payments source 2025-06-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.03 · Open Payments source 2025-06-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.15 · Open Payments source 2025-06-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.14 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.25 · Open Payments source 2025-06-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-07-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.09 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.95 · Open Payments source 2025-07-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.72 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 · Open Payments source 2025-07-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.05 · Open Payments source 2025-07-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.38 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,790.00 · Open Payments source 2025-08-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.88 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-08-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.26 · Open Payments source 2025-08-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.74 · Open Payments source 2025-08-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.42 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $94.89 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 · Open Payments source 2025-09-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.95 · Open Payments source 2025-09-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.73 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.59 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.36 · Open Payments source 2025-09-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.38 · Open Payments source 2025-09-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.97 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.00 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $112.00 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $196.00 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $112.00 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $359.80 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.00 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $91.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $328.48 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.75 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.19 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.87 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.33 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.57 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.25 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $196.00 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $147.00 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.33 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.04 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.90 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.10 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.70 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.89 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.49 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.73 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.74 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.71 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $105.47 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.39 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $102.64 · Open Payments source 2025-11-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.65 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.82 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.08 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $845.84 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.76 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.70 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.29 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,550.00 · Open Payments source 2025-11-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.70 · Open Payments source 2025-11-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $735.74 · Open Payments source 2025-11-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.31 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,550.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.66 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.27 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-12-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.02 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $930.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $930.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $930.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,790.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,170.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $101.60 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.65 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,240.00 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,480.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$21,851.96	40	2025
Source payment records 2025-01-08 · Axsome Therapeutics, Inc. · $1,250.00 · Open Payments source 2025-01-08 · Axsome Therapeutics, Inc. · $189.70 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $1,250.00 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $182.00 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $60.36 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $78.04 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $45.30 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $32.93 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $48.79 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $29.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $125.13 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $26.77 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $469.66 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $587.98 · Open Payments source 2025-04-03 · Axsome Therapeutics, Inc. · $4,250.00 · Open Payments source 2025-04-03 · Axsome Therapeutics, Inc. · $14.78 · Open Payments source 2025-04-03 · Axsome Therapeutics, Inc. · $114.80 · Open Payments source 2025-04-09 · Axsome Therapeutics, Inc. · $1,250.00 · Open Payments source 2025-04-11 · Axsome Therapeutics, Inc. · $500.00 · Open Payments source 2025-04-21 · Axsome Therapeutics, Inc. · $1,250.00 · Open Payments source 2025-04-21 · Axsome Therapeutics, Inc. · $500.00 · Open Payments source 2025-04-21 · Axsome Therapeutics, Inc. · $194.60 · Open Payments source 2025-04-28 · Axsome Therapeutics, Inc. · $500.00 · Open Payments source 2025-05-09 · Axsome Therapeutics, Inc. · $1,250.00 · Open Payments source 2025-05-09 · Axsome Therapeutics, Inc. · $266.00 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $21.32 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $1,250.00 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $182.00 · Open Payments source 2025-06-25 · Axsome Therapeutics, Inc. · $500.00 · Open Payments source 2025-07-22 · Axsome Therapeutics, Inc. · $34.50 · Open Payments source 2025-07-22 · Axsome Therapeutics, Inc. · $1,250.00 · Open Payments source 2025-07-22 · Axsome Therapeutics, Inc. · $140.00 · Open Payments source 2025-08-19 · Axsome Therapeutics, Inc. · $1,625.00 · Open Payments source 2025-08-19 · Axsome Therapeutics, Inc. · $96.67 · Open Payments source 2025-08-19 · Axsome Therapeutics, Inc. · $135.80 · Open Payments source 2025-08-28 · Axsome Therapeutics, Inc. · $625.00 · Open Payments source 2025-09-22 · Axsome Therapeutics, Inc. · $500.00 · Open Payments source 2025-10-30 · Axsome Therapeutics, Inc. · $25.38 · Open Payments source 2025-11-10 · Axsome Therapeutics, Inc. · $500.00 · Open Payments source 2025-11-11 · Axsome Therapeutics, Inc. · $500.00 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$18,799.85	44	2025
Source payment records 2025-01-30 · Otsuka America Pharmaceutical, Inc. · $7.70 · Open Payments source 2025-02-14 · Otsuka America Pharmaceutical, Inc. · $20.94 · Open Payments source 2025-02-19 · Otsuka America Pharmaceutical, Inc. · $125.00 · Open Payments source 2025-02-24 · Lundbeck LLC · $16.25 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $905.00 · Open Payments source 2025-03-25 · Otsuka America Pharmaceutical, Inc. · $22.93 · Open Payments source 2025-04-02 · Lundbeck LLC · $13.94 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $7.83 · Open Payments source 2025-04-22 · Otsuka America Pharmaceutical, Inc. · $151.00 · Open Payments source 2025-04-22 · Otsuka America Pharmaceutical, Inc. · $24.11 · Open Payments source 2025-04-25 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-05-06 · Otsuka America Pharmaceutical, Inc. · $19.54 · Open Payments source 2025-05-07 · Otsuka America Pharmaceutical, Inc. · $905.00 · Open Payments source 2025-05-08 · Otsuka America Pharmaceutical, Inc. · $1,171.00 · Open Payments source 2025-05-09 · Otsuka America Pharmaceutical, Inc. · $161.00 · Open Payments source 2025-05-13 · Otsuka America Pharmaceutical, Inc. · $16.24 · Open Payments source 2025-05-14 · Otsuka America Pharmaceutical, Inc. · $124.74 · Open Payments source 2025-05-14 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-05-21 · Otsuka America Pharmaceutical, Inc. · $15.99 · Open Payments source 2025-05-21 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-05-23 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $8.62 · Open Payments source 2025-07-31 · Otsuka America Pharmaceutical, Inc. · $8.37 · Open Payments source 2025-09-04 · Otsuka America Pharmaceutical, Inc. · $5.50 · Open Payments source 2025-09-15 · Otsuka America Pharmaceutical, Inc. · $13.17 · Open Payments source 2025-09-30 · Otsuka America Pharmaceutical, Inc. · $3.16 · Open Payments source 2025-10-06 · Otsuka America Pharmaceutical, Inc. · $18.71 · Open Payments source 2025-10-10 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-10-21 · Otsuka America Pharmaceutical, Inc. · $9.59 · Open Payments source 2025-11-03 · Otsuka America Pharmaceutical, Inc. · $17.43 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $126.00 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $120.80 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-11-13 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-11-14 · Otsuka America Pharmaceutical, Inc. · $5.00 · Open Payments source 2025-11-14 · Otsuka America Pharmaceutical, Inc. · $129.50 · Open Payments source 2025-12-08 · Otsuka America Pharmaceutical, Inc. · $27.12 · Open Payments source 2025-12-10 · Otsuka America Pharmaceutical, Inc. · $17.87 · Open Payments source 2025-12-12 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-12-15 · Otsuka America Pharmaceutical, Inc. · $20.63 · Open Payments source 2025-12-16 · Otsuka America Pharmaceutical, Inc. · $18.17 · Open Payments source 2025-12-19 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source 2025-12-19 · Otsuka America Pharmaceutical, Inc. · $1,322.00 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$12,175.13	40	2025
Source payment records 2025-01-08 · ABBVIE INC. · $29.42 · Open Payments source 2025-01-16 · ABBVIE INC. · $5.67 · Open Payments source 2025-02-06 · ABBVIE INC. · $21.63 · Open Payments source 2025-02-21 · ABBVIE INC. · $10.31 · Open Payments source 2025-03-21 · ABBVIE INC. · $9.09 · Open Payments source 2025-03-24 · ABBVIE INC. · $20.67 · Open Payments source 2025-03-27 · ABBVIE INC. · $27.56 · Open Payments source 2025-04-01 · ABBVIE INC. · $6.10 · Open Payments source 2025-04-10 · ABBVIE INC. · $28.92 · Open Payments source 2025-04-15 · ABBVIE INC. · $10.87 · Open Payments source 2025-04-17 · ABBVIE INC. · $21.49 · Open Payments source 2025-04-25 · ABBVIE INC. · $1,500.00 · Open Payments source 2025-05-05 · ABBVIE INC. · $1,500.00 · Open Payments source 2025-05-06 · ABBVIE INC. · $18.02 · Open Payments source 2025-05-08 · ABBVIE INC. · $26.85 · Open Payments source 2025-05-14 · ABBVIE INC. · $21.58 · Open Payments source 2025-05-28 · ABBVIE INC. · $2,100.00 · Open Payments source 2025-05-29 · ABBVIE INC. · $5.25 · Open Payments source 2025-06-09 · ABBVIE INC. · $6.31 · Open Payments source 2025-06-10 · ABBVIE INC. · $15.80 · Open Payments source 2025-06-17 · ABBVIE INC. · $6.42 · Open Payments source 2025-06-17 · ABBVIE INC. · $23.58 · Open Payments source 2025-06-17 · ABBVIE INC. · $112.00 · Open Payments source 2025-06-27 · ABBVIE INC. · $6.63 · Open Payments source 2025-07-02 · ABBVIE INC. · $2,100.00 · Open Payments source 2025-07-10 · ABBVIE INC. · $19.06 · Open Payments source 2025-07-10 · ABBVIE INC. · $98.00 · Open Payments source 2025-07-17 · ABBVIE INC. · $2,100.00 · Open Payments source 2025-08-06 · ABBVIE INC. · $4.51 · Open Payments source 2025-09-02 · ABBVIE INC. · $4.64 · Open Payments source 2025-09-16 · ABBVIE INC. · $7.45 · Open Payments source 2025-09-18 · ABBVIE INC. · $3.56 · Open Payments source 2025-09-23 · ABBVIE INC. · $5.04 · Open Payments source 2025-09-30 · ABBVIE INC. · $11.50 · Open Payments source 2025-10-02 · ABBVIE INC. · $105.00 · Open Payments source 2025-10-02 · ABBVIE INC. · $15.44 · Open Payments source 2025-10-23 · ABBVIE INC. · $2,100.00 · Open Payments source 2025-11-04 · ABBVIE INC. · $25.07 · Open Payments source 2025-11-11 · ABBVIE INC. · $27.83 · Open Payments source 2025-12-02 · ABBVIE INC. · $13.86 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$8,105.08	18	2025
Source payment records 2025-05-27 · Vanda Pharmaceuticals Inc. · $36.01 · Open Payments source 2025-05-27 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-05-27 · Vanda Pharmaceuticals Inc. · $117.60 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $647.66 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $178.12 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $105.01 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $4,455.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $252.50 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $112.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $64.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $219.22 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $69.90 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $3.99 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $32.61 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $49.55 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $29.52 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $2.66 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $79.73 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$6,141.38	27	2025
Source payment records 2025-01-15 · E.R. Squibb & Sons, L.L.C. · $11.69 · Open Payments source 2025-03-18 · E.R. Squibb & Sons, L.L.C. · $15.69 · Open Payments source 2025-04-03 · E.R. Squibb & Sons, L.L.C. · $17.28 · Open Payments source 2025-06-03 · E.R. Squibb & Sons, L.L.C. · $12.61 · Open Payments source 2025-06-30 · E.R. Squibb & Sons, L.L.C. · $14.31 · Open Payments source 2025-07-16 · E.R. Squibb & Sons, L.L.C. · $84.46 · Open Payments source 2025-07-17 · E.R. Squibb & Sons, L.L.C. · $21.52 · Open Payments source 2025-07-30 · E.R. Squibb & Sons, L.L.C. · $9.70 · Open Payments source 2025-08-07 · E.R. Squibb & Sons, L.L.C. · $9.98 · Open Payments source 2025-08-19 · E.R. Squibb & Sons, L.L.C. · $33.38 · Open Payments source 2025-08-29 · E.R. Squibb & Sons, L.L.C. · $1,600.00 · Open Payments source 2025-09-09 · E.R. Squibb & Sons, L.L.C. · $125.85 · Open Payments source 2025-09-11 · E.R. Squibb & Sons, L.L.C. · $5.08 · Open Payments source 2025-09-25 · E.R. Squibb & Sons, L.L.C. · $4.72 · Open Payments source 2025-09-25 · E.R. Squibb & Sons, L.L.C. · $25.34 · Open Payments source 2025-09-25 · E.R. Squibb & Sons, L.L.C. · $2,240.00 · Open Payments source 2025-10-08 · E.R. Squibb & Sons, L.L.C. · $126.00 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $64.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $1,068.07 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $49.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 · Open Payments source 2025-10-27 · E.R. Squibb & Sons, L.L.C. · $12.53 · Open Payments source 2025-11-10 · E.R. Squibb & Sons, L.L.C. · $15.40 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$5,834.72	12	2025
Source payment records 2025-05-02 · Alkermes, Inc. · $560.00 · Open Payments source 2025-07-08 · Alkermes, Inc. · $16.17 · Open Payments source 2025-07-29 · Alkermes, Inc. · $5.07 · Open Payments source 2025-07-29 · Alkermes, Inc. · $6.77 · Open Payments source 2025-08-13 · Alkermes, Inc. · $560.00 · Open Payments source 2025-08-23 · Alkermes, Inc. · $15.95 · Open Payments source 2025-08-29 · Alkermes, Inc. · $31.15 · Open Payments source 2025-09-11 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-09-18 · Alkermes, Inc. · $120.06 · Open Payments source 2025-10-03 · Alkermes, Inc. · $1,800.00 · Open Payments source 2025-10-14 · Alkermes, Inc. · $19.55 · Open Payments source 2025-10-23 · Alkermes, Inc. · $1,350.00 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$979.00	2	2025
Source payment records 2025-04-27 · Teva Pharmaceuticals USA, Inc. · $761.00 · Open Payments source 2025-11-30 · Teva Pharmaceuticals USA, Inc. · $218.00 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$130.55	7	2025
Source payment records 2025-01-06 · Otsuka America Pharmaceutical, Inc. · $29.02 · Open Payments source 2025-01-16 · Otsuka America Pharmaceutical, Inc. · $21.00 · Open Payments source 2025-05-04 · Otsuka America Pharmaceutical, Inc. · $28.29 · Open Payments source 2025-05-05 · Otsuka America Pharmaceutical, Inc. · $0.33 · Open Payments source 2025-08-04 · Otsuka America Pharmaceutical, Inc. · $5.51 · Open Payments source 2025-08-04 · Otsuka America Pharmaceutical, Inc. · $24.76 · Open Payments source 2025-09-22 · Otsuka America Pharmaceutical, Inc. · $21.64 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$101.53	6	2025
Source payment records 2025-01-16 · Otsuka America Pharmaceutical, Inc. · $21.00 · Open Payments source 2025-05-04 · Otsuka America Pharmaceutical, Inc. · $28.29 · Open Payments source 2025-05-05 · Otsuka America Pharmaceutical, Inc. · $0.33 · Open Payments source 2025-08-04 · Otsuka America Pharmaceutical, Inc. · $5.51 · Open Payments source 2025-08-04 · Otsuka America Pharmaceutical, Inc. · $24.76 · Open Payments source 2025-09-22 · Otsuka America Pharmaceutical, Inc. · $21.64 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$43.96	4	2025
Source payment records 2025-07-08 · Alkermes, Inc. · $16.17 · Open Payments source 2025-07-29 · Alkermes, Inc. · $5.07 · Open Payments source 2025-07-29 · Alkermes, Inc. · $6.77 · Open Payments source 2025-08-23 · Alkermes, Inc. · $15.95 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$19.85	1	2025
Source payment records 2025-09-30 · Supernus Pharmaceuticals, Inc. · $19.85 · Open Payments source
Dyanavel XR Normalized: dyanavel xr	Drug	Tris Pharma Inc	$17.36	1	2025
Source payment records 2025-09-15 · Tris Pharma Inc · $17.36 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$16.54	1	2025
Source payment records 2025-01-31 · Neurocrine BioSciences, Inc. · $16.54 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Auvelity auvelity	2025	Auvelity	2024	135	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	43 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	46 Beneficiary count suppressed	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D
Qelbree qelbree	2025	Qelbree	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	59	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	103	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	103	17
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	135	25
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	43	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	59	16
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	46	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	NUEDEXTA open payments reported associated product	CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901	Nuedexta · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	59	16
Supernus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	Qelbree open payments reported associated product	CMS Open Payments — General Payments 61278 supporting records · 18421 recipient NPIs · example record 1244861775	Qelbree · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Alprazolam	Alprazolam	265	34
Trazodone Hcl	Trazodone Hcl	233	40
Quetiapine Fumarate	Quetiapine Fumarate	197	36
Clonazepam	Clonazepam	175	26
Sertraline Hcl	Sertraline Hcl	139	26
Auvelity	Dextromethorphan Hbr/Bupropion	135	25
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	120	13
Venlafaxine Hcl Er	Venlafaxine Hcl	112	20
Vraylar	Cariprazine Hcl	103	17
Escitalopram Oxalate	Escitalopram Oxalate	95	16
Prazosin Hcl	Prazosin Hcl	93	14
Zolpidem Tartrate	Zolpidem Tartrate	90	14
Duloxetine Hcl	Duloxetine Hcl	88	13
Lamotrigine	Lamotrigine	87	15
Quviviq	Daridorexant Hcl	82	17
Propranolol Hcl	Propranolol Hcl	78	12
Vilazodone Hcl	Vilazodone Hcl	76	13
Bupropion Hcl Sr	Bupropion Hcl	75	13
Gabapentin	Gabapentin	72	15
Aripiprazole	Aripiprazole	64	17
Hydroxyzine Hcl	Hydroxyzine Hcl	62	16
Diazepam	Diazepam	59	suppressed
Rexulti	Brexpiprazole	59	16
Lorazepam	Lorazepam	57	11
Bupropion Xl	Bupropion Hcl	55	14
Ingrezza	Valbenazine Tosylate	46	suppressed
Clozapine	Clozapine	45	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	43	suppressed
Buspirone Hcl	Buspirone Hcl	43	suppressed
Caplyta	Lumateperone Tosylate	43	suppressed
Paroxetine Hcl	Paroxetine Hcl	43	suppressed
Trintellix	Vortioxetine Hydrobromide	43	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	42	suppressed
Mirtazapine	Mirtazapine	41	suppressed
Benztropine Mesylate	Benztropine Mesylate	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Topiramate	Topiramate	33	suppressed
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	27	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	21	suppressed
Bupropion Hcl	Bupropion Hcl	21	suppressed
Divalproex Sodium	Divalproex Sodium	21	suppressed
Lurasidone Hcl	Lurasidone Hcl	21	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	20	17
Vyvanse	Lisdexamfetamine Dimesylate	19	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	18	18
Haloperidol	Haloperidol	16	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	15	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	14	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	14	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	14	suppressed
Qelbree	Viloxazine Hcl	14	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	11	suppressed
Olanzapine	Olanzapine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$161,530.52 · 321 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, Auvelity, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, INGREZZA, LYBALVI, Qelbree, REXULTI, UZEDY, VRAYLAR	9	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Auvelity play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error